Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4847.72% is 113% below its 5-year average of -2273.74%, near the high end of its 5-year range (-16451.88%–51.03%).
10.41% below its 12-month average of -4390.76%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3610.97%.
EBITDA MARGIN
-4847.72%
EBITDA MARGIN AVG TTM
-4390.76%
EBITDA MARGIN AVG 3Y
-3501.64%
EBITDA MARGIN AVG 5Y
-2273.74%
EBITDA MARGIN AVG 10Y
-3939.61%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-10.41%
CURRENT VS 3Y AVG
-38.44%
CURRENT VS 5Y AVG
-113.21%
CURRENT VS 10Y AVG
-23.05%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Co-Diagnostics, Inc.
Market Cap
$6.88M
EBITDA Margin
-4847.72%
TTM Avg
-4390.76%
3Y Avg
-3501.64%
5Y Avg
-2273.74%
Market Cap
$6.76M
EBITDA Margin
-10.17%
TTM Avg
-10.02%
3Y Avg
-12.29%
5Y Avg
-11.98%
Market Cap
$6.74M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
Market Cap
$7.01M
EBITDA Margin
-2068.24%
TTM Avg
-1510.83%
3Y Avg
-1474.78%
5Y Avg
-1474.78%
Market Cap
$7.03M
EBITDA Margin
3.56%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$6.72M
EBITDA Margin
-430.70%
TTM Avg
-678.73%
3Y Avg
-962.21%
5Y Avg
-5357.45%
Market Cap
$7.31M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$6.44M
EBITDA Margin
-485.73%
TTM Avg
-485.73%
3Y Avg
-485.73%
5Y Avg
-485.73%
Market Cap
$6.34M
EBITDA Margin
-110.02%
TTM Avg
-99.60%
3Y Avg
-109.65%
5Y Avg
-93.07%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Co-Diagnostics, Inc. (CODX) | $6.88M | -4847.72% | -4390.76% | -3501.64% | -2273.74% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -10.17% | -10.02% | -12.29% | -11.98% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| KALA BIO, Inc. (KALA)vs › | $7.01M | -2068.24% | -1510.83% | -1474.78% | -1474.78% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | 3.56% | 3.56% | 3.56% | 3.56% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -430.70% | -678.73% | -962.21% | -5357.45% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.29% | -74.83% | -125.41% | -344.12% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -485.73% | -485.73% | -485.73% | -485.73% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -110.02% | -99.60% | -109.65% | -93.07% |
| Longeveron Inc. (LGVN)vs › | $7.64M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
Gross Margin
64.3%
EBITDA Margin
-4847.7%
Operating Margin
-5025.5%
Net Margin
-6523.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3610.97% |
| 2026-03-31 | -6134.10% |
| 2025-12-31 | -2800.91% |
| 2025-09-30 | -4640.57% |
| 2025-06-30 | -4767.26% |
| 2025-03-31 | -16451.88% |
| 2024-12-31 | -7734.74% |
| 2024-09-30 | -1541.58% |
| 2024-06-30 | -276.33% |
| 2024-03-31 | -3928.39% |
| 2023-12-31 | -323.82% |
| 2023-09-30 | -351.62% |
| 2023-06-30 | -5909.42% |
| 2023-03-31 | -1600.55% |
| 2022-12-31 | -1842.53% |
| 2022-09-30 | -122.15% |
| 2022-06-30 | -74.11% |
| 2022-03-31 | 44.37% |
| 2021-12-31 | 51.03% |
| 2021-09-30 | 45.59% |
| 2021-06-30 | 43.36% |
| 2021-03-31 | 51.95% |
| 2020-12-31 | 59.26% |
| 2020-09-30 | 55.34% |
| 2020-06-30 | 61.29% |
| 2020-03-31 | -68.53% |
| 2019-12-31 | -1477.69% |
| 2019-09-30 | -3941.40% |
| 2019-06-30 | -2191.95% |
| 2019-03-31 | -36494.82% |
| 2018-12-31 | -16724.74% |
| 2018-09-30 | -17029.22% |
| 2018-06-30 | -13827.88% |
| 2018-03-31 | -13046.91% |
| 2017-12-31 | -57011.55% |
| 2017-09-30 | -69000.92% |
| 2017-06-30 | -27975.10% |
| 2016-03-31 | -4474.35% |
| 2015-12-31 | -4356.14% |
